Abstract: Objective: To investigate the effects of fenofibrate combined with ezromycin on metabolism and endothelial function in type 2 diabetes complicated with hyperlipidemia. Methods: 120 patients with type 2 diabetes and hyperlipidemia from January in our hospital from 2013 to June 2018 were randomly divided into experimental group and control group, 60 cases in each group. The experimental group was treated with fenofibrate combined with ezumab, while the control group was only treated with ezumab. The changes of metabolic index and endothelial function in the two groups were observed after treatment. Results: The effective rate of treatment in the experimental group was higher than that in the control group. After treatment, serum TC, TG, LDL-C, FPG, 2hPG, postprandial maximum blood glucose and PAI-1 were lower than those in the control group, while HDL-C, NO, ET-1 were higher than those in the control group (P < 0.05). Conclusion: Fenofibrate combined with Ezymib has a good effect in the treatment of type 2 diabetes complicated with hyperlipidemia, and can effectively improve the metabolic index and endothelial function.